Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02965378 | Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 / Phase 3 | 43 | SWOG Cancer Research NetworkNETWORK | 2 | May 27, 2021 | clinicaltrials |
| NCT04874844 | JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety | unknown | Phase 2 / Phase 3 | 420 | Beijing Dongfang Biotech Co., Ltd.INDUSTRY | 0 | May 10, 2021 |
| clinicaltrials |
| NCT03296163 | A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLA) | completed | Phase 3 | 627 | mAbxience Research S.L.INDUSTRY | 18 | Apr 26, 2021 | clinicaltrials |
| NCT04840290 | A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC | unknown | Phase 3 | 30 | Tang-Du HospitalOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | terminated | Phase 3 | 1,048 | Daiichi SankyoINDUSTRY | 23 | Apr 6, 2021 | clinicaltrials |
| NCT02667743 | Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC | unknown | Phase 3 | 454 | Shanghai Yizhong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04797806 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC(SAINT) | unknown | Phase 3 | 206 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04772287 | Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) | not yet recruiting | Phase 3 | 341 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 26, 2021 | clinicaltrials |
| NCT02893332 | Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)(Sindas) | terminated | Phase 3 | 200 | Sichuan Provincial People's HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00130728 | A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | completed | Phase 3 | 636 | Genentech, Inc.INDUSTRY | 1 | Jan 14, 2021 | clinicaltrials |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer(ATRACT-1) | terminated | Phase 3 | 1,285 | Novartis PharmaceuticalsINDUSTRY | 26 | Dec 24, 2020 | clinicaltrials |
| NCT00738387 | A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer(ATTRACT-2) | terminated | Phase 3 | 900 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 24, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT01639001 | A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients | completed | Phase 3 | 207 | PfizerINDUSTRY | 5 | Dec 8, 2020 | clinicaltrials |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.(PIONEER) | terminated | Phase 3 | 600 | CTI BioPharmaINDUSTRY | 11 | Nov 24, 2020 | clinicaltrials |
| NCT00410683 | Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery(LUNG ART) | unknown | Phase 3 | 500 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT01355497 | Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum | completed | Phase 3 | 330 | GTxINDUSTRY | 1 | Nov 9, 2020 | clinicaltrials |
| NCT03402048 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial(EPIC) | unknown | Phase 3 | 567 | University of Turin, ItalyOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00880971 | Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer | completed | Phase 3 | 394 | Chinese Academy of Medical SciencesOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01544179 | A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone(IMPRESS) | completed | Phase 3 | 265 | AstraZenecaINDUSTRY | 11 | Sep 25, 2020 | clinicaltrials |
| NCT04416035 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC(NSCLC) | unknown | Phase 3 | 608 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04500704 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC(ACROSS1) | unknown | Phase 3 | 166 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500717 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation(ACROSS2) | unknown | Phase 3 | 460 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02395172 | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | completed | Phase 3 | 792 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 29 | Aug 3, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT04465968 | Efficacy and Safety of CRT, Durvalumab and Surgery for SST(DEEP_OCEAN) | not yet recruiting | Phase 3 | 84 | National Cancer Center Hospital EastOTHER | 0 | Jul 10, 2020 | clinicaltrials |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy(IDA) | terminated | Phase 3 | 230 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT03134872 | A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | completed | Phase 3 | 419 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | terminated | Phase 2 / Phase 3 | 135 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT04203485 | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 762 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 8, 2020 | clinicaltrials |
| NCT02161991 | Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers | completed | Phase 3 | 244 | Hunan Province Tumor HospitalOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02076477 | The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）(OITROLC) | unknown | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT03331588 | Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer | completed | Phase 3 | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT01405079 | Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation(ADJUVANT) | unknown | Phase 3 | 222 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT02416739 | Anticancer Activity of Nicotinamide on Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Il Yeong Park, Ph.D.OTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239833 | A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | unknown | Phase 3 | 240 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Jan 27, 2020 | clinicaltrials |
| NCT03827577 | OMEGA, Local Ablative Therapy in Oligometastatic NSCLC(OMEGA) | unknown | Phase 3 | 195 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02272413 | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 671 | Boehringer IngelheimINDUSTRY | 28 | Jan 13, 2020 | clinicaltrials |
| NCT01667562 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer(ESSENCE) | completed | Phase 3 | 375 | Hoffmann-La RocheINDUSTRY | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02008227 | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy(OAK) | completed | Phase 3 | 1,225 | Hoffmann-La RocheINDUSTRY | 31 | Dec 20, 2019 | clinicaltrials |
| NCT03529084 | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 22, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04009317 | Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00540514 | Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 3 | 1,052 | CelgeneINDUSTRY | 2 | Oct 29, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2021source: clinicaltrials